What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yinglian, Chen, Simiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989390/
https://www.ncbi.nlm.nih.gov/pubmed/33635318
http://dx.doi.org/10.1093/jtm/taab026
_version_ 1783668936764555264
author Hu, Yinglian
Chen, Simiao
author_facet Hu, Yinglian
Chen, Simiao
author_sort Hu, Yinglian
collection PubMed
description Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.
format Online
Article
Text
id pubmed-7989390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79893902021-04-01 What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective Hu, Yinglian Chen, Simiao J Travel Med Perspective Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model. Oxford University Press 2021-02-25 /pmc/articles/PMC7989390/ /pubmed/33635318 http://dx.doi.org/10.1093/jtm/taab026 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of International Society of Travel Medicine. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspective
Hu, Yinglian
Chen, Simiao
What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title_full What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title_fullStr What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title_full_unstemmed What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title_short What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
title_sort what can we learn from covid-19 vaccine r&d in china? a discussion from a public policy perspective
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989390/
https://www.ncbi.nlm.nih.gov/pubmed/33635318
http://dx.doi.org/10.1093/jtm/taab026
work_keys_str_mv AT huyinglian whatcanwelearnfromcovid19vaccinerdinchinaadiscussionfromapublicpolicyperspective
AT chensimiao whatcanwelearnfromcovid19vaccinerdinchinaadiscussionfromapublicpolicyperspective

Ejemplares similares